Supplemental Figure 1

2
Supplemental Figure 1 t = 0 min t = 5 min t = 10 min t = 15 min t = 20 min B. Axonal Blebbing A. Growth Cone Ruffling t = 0 min t = 5 min t = 10 min t = 15 min t = 20 min 0 20 40 60 80 100 0 0 .5 1 1.5 2 2 .5 3 3 .5 Percent A verag e P o sitive V elo city (µ m /m in) N o Incubation 4 H our Incubation D. Average Positive Particle Velocity Histogram C. WGA Kymograph (4 hr incubation) Position Time Cell Body Growth Cone 0 min 20 min E. Confocal Imaging of WGA WGA *

description

B. Axonal Blebbing. t = 0 min. t = 0 min. t = 5 min. t = 5 min. t = 10 min. t = 10 min. t = 15 min. t = 15 min. t = 20 min. t = 20 min. A. Growth Cone Ruffling. D.Average Positive Particle Velocity Histogram. C. WGA Kymograph (4 hr incubation). 0 min. Time. *. 20 min. - PowerPoint PPT Presentation

Transcript of Supplemental Figure 1

Page 1: Supplemental Figure 1

Supplemental Figure 1

t = 0 min

t = 5 min

t = 10 min

t = 15 min

t = 20 min

B. Axonal Blebbing A. Growth Cone Ruffling

t = 0 min

t = 5 min

t = 10 min

t = 15 min

t = 20 min

0

20

40

60

80

100

0 0.5 1 1.5 2 2.5 3 3.5

Perc

en

t

Average Positive Velocity (µm/ min)

No Incubation

4 Hour I ncubation

D. Average Positive Particle Velocity Histogram

C. WGA Kymograph (4 hr incubation)

Position

Tim

e

Cell Body Growth Cone

0 min

20 min

E. Confocal Imaging of WGA

WGA

*

Page 2: Supplemental Figure 1

A. Average Positive Particle Velocity Histogram

B. Average Positive Particle Velocity Histogram (within 30 µm of the edge)

D. Average Negative Particle Velocity Histogram (within 30 µm of the edge)

C. Average Negative Particle Velocity Histogram

0

20

40

60

80

100

120

0 0.5 1 1.5

Perc

en

t

Average Positive Velocity (μm/ min)

NC

NNC

SCC

SCNC

0

20

40

60

80

100

120

0 0.5 1 1.5

Perc

en

t

Average Positive Velocity (μm/ min)

NC

NNC

SCC

SCNC

0

20

40

60

80

100

-2 -1.5 -1 -0.5 0

Perc

en

t

Average Positive Velocity (μm/ min)

NC

NNC

SCC

SCNC

0

20

40

60

80

100

-2 -1.5 -1 -0.5 0

Perc

en

t

Average Positive Velocity (μm/ min)

NC

NNC

SCC

SCNC

Supplemental Figure 2


Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,

Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

List of Supplemental Digital Content Supplemental Figure 1 ...

List of Supplemental Digital Content Supplemental Figure 1 ...

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z ...

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z ...

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.

Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.

Supplemental Figure 1.

Supplemental Figure 1.

BolteusBordey Supplemental Figure 1

BolteusBordey Supplemental Figure 1

Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

Supplemental Figure 1.

Supplemental Figure 1.

Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Figure legends: Supplemental Figure 1 A) TAA;

Figure legends: Supplemental Figure 1 A) TAA;

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.

Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.